Latest Infection Prevention News

Nanosonics Limited has announced a $20 million on-market share buy-back program for FY26, underscoring its robust financial health and confidence in future growth driven by new product innovations.

Nanosonics delivered a robust FY25 with 17% revenue growth and a 72% jump in profit before tax, propelled by next-gen trophon devices and advancing CORIS commercialisation.

Nanosonics has secured FDA clearance for its next-generation trophon3 device and trophon2 Plus software upgrade, setting the stage for significant growth in the US medical disinfection market.

Nanosonics has launched trophon3, its next-generation ultrasound disinfection device, alongside a software upgrade for existing users, promising faster cycles and enhanced digital integration.

Next Science Limited has agreed to sell most of its assets to Demetra Holdings for US$50 million, with plans to return an estimated US$30 million net proceeds to shareholders pending approval.

Nanosonics delivers a robust H1 FY25 trading update, reporting an 18% rise in revenue to $93.6 million and a profit before tax of $10.9 million, signaling strong momentum in its infection prevention business.